Tourette's Syndrome
Recent clinical, regulatory, research and industry developments relating to this disease.
Emerging therapies for childhood-onset movement disorders.
Cannabinoids for Medical Use: A Systematic Review and Meta-analysis.
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
- 2 clinical trials expected to report results, the earliest in Q3 2027.
- 1 industry development reported.
- Q3 2027A Randomized Placebo-Controlled Trial of Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders
- Q3 2027Study on the Mechanism of Pei Tu Ning Feng Tang in Alleviating Tourette Syndrome Via Functional Near-Infrared Spectroscopy (fNIRS) and the DA-MAPK-BDNF Pathway
Clinical MilestonesViewHide
- 2026-07-27A Randomized Placebo-Controlled Trial of Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental DisordersResults expected Q3 2027
- 2026-07-14Study on the Mechanism of Pei Tu Ning Feng Tang in Alleviating Tourette Syndrome Via Functional Near-Infrared Spectroscopy (fNIRS) and the DA-MAPK-BDNF PathwayResults expected Q3 2027
- 2026-06-01A Double-blind, Placebo-controlled, Phase 2b, Multi-center, Twelve-week Prospective Study to Evaluate the Efficacy and Safety of Gemlapodect in Adult and Adolescent Patients With Tourette SyndromePrimary completion
- 2026-03-01MultitArget STereotactic Electrophysiological Recording and Stimulation for Tourette SyndromePrimary completion
Industry & MarketViewHide
- 2026-08-19<![CDATA[Neuropsychiatry in the News: Wearable Technology for Parkinson Disease, Ecopipam for Tourette Syndrome]]>Industry · Psychiatric Times
- 2026-08-19Industry<![CDATA[Neuropsychiatry in the News: Wearable Technology for Parkinson Disease, Ecopipam for Tourette Syndrome]]>Industry · Psychiatric Times
- 2026-07-27ClinicalA Randomized Placebo-Controlled Trial of Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental DisordersResults expected Q3 2027
- 2026-07-14ClinicalStudy on the Mechanism of Pei Tu Ning Feng Tang in Alleviating Tourette Syndrome Via Functional Near-Infrared Spectroscopy (fNIRS) and the DA-MAPK-BDNF PathwayResults expected Q3 2027
- 2026-06-01ClinicalA Double-blind, Placebo-controlled, Phase 2b, Multi-center, Twelve-week Prospective Study to Evaluate the Efficacy and Safety of Gemlapodect in Adult and Adolescent Patients With Tourette SyndromePrimary completion
- 2026-03-01ClinicalMultitArget STereotactic Electrophysiological Recording and Stimulation for Tourette SyndromePrimary completion
Clinical trials
The current development programme across all trial phases.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Major themes1
- Movement Disorders1
Leading journals2
- Current opinion in pediatrics1
- JAMA1
Leading researchers8
- Deshpande S1
- Di Nisio M1
- Duffy S1
- Ebrahimi-Fakhari D1
- Hernandez AV1
- Keurentjes JC1
- Kleijnen J1
- Lang S1
Affiliations (unnormalised)6
- F.M. Kirby Neurobiology Center1
- Institut für Epidemiologie und kongenitale Erkrankungen1
- Medical School1
- Radboud University Medical Center1
- School of Social and Community Medicine1
- The Hospital for Sick Children1
Associated genes
Genes associated with this disease in the canonical knowledge graph (Open Targets evidence). Number shows the association score.
Disease biology
Proteins whose encoding gene is associated with this disease, reached through the canonical gene→disease graph. Number shows the gene's association score.
Reference
Authoritative identity, definition & identifiers.
A neuropsychological disorder related to alterations in DOPAMINE metabolism and neurotransmission involving frontal-subcortical neuronal circuits. Both multiple motor and one or more vocal tics need to be present with TICS occurring many times a day, nearly daily, over a period of more than one year. The onset is before age 18 and the disturbance is not due to direct physiological effects of a substance or another medical condition. The disturbance causes marked distress or significant impairment in social, occupational, or other important areas of functioning. (From DSM-IV, 1994; Neurol Clin 1997 May;15(2):357-79)
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.